GM 2941

Drug Profile

GM 2941

Latest Information Update: 07 Feb 2001

Price : $50

At a glance

  • Originator Glycomed
  • Developer Glycomed; University of Michigan Medical School
  • Class Antineoplastics; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lung disorders

Most Recent Events

  • 07 Feb 2001 Discontinued-Preclinical for Lung disorders in USA (Unknown route)
  • 05 Aug 1998 New profile
  • 05 Aug 1998 Preclinical development for Lung disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top